Colorectal cancer Medical Services in China

Colorectal cancer (CRC) is a malignant neoplasm arising from the epithelial lining of the colon or rectum. It typically develops from precancerous adenomatous polyps through a stepwise accumulation of genetic and epigenetic alterations—most notably in the APC, KRAS, TP53, and mismatch repair (MMR) genes—culminating in uncontrolled cellular proliferation, invasion, and metastasis. The disease follows the well-established adenoma-carcinoma sequence in ~85% of sporadic cases; however, hereditary forms—including Lynch syndrome (hereditary non-polyposis colorectal cancer) and familial adenomatous polyposis (FAP)—account for 5–10% of diagnoses and confer significantly elevated lifetime risk. Globally, CRC is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, with over 1.9 million new cases and nearly 935,000 deaths annually (GLOBOCAN 2022). In China, incidence has risen sharply over the past two decades—now exceeding 550,000 new cases per year—driven by urbanization, aging populations, and shifts toward Westernized diets high in red/processed meats, low in dietary fiber, and associated with sedentary lifestyles. Key modifiable risk factors include obesity, type 2 diabetes, heavy alcohol consumption, smoking, and long-term inflammatory bowel disease (e.g., ulcerative colitis or Crohn’s colitis). Non-modifiable risks encompass age (>50 years), personal or family history of CRC or advanced adenomas, and inherited syndromes. Early-stage CRC is often asymptomatic, underscoring the critical importance of screening—particularly fecal immunochemical testing (FIT), colonoscopy, and multi-target stool DNA tests. When symptoms emerge, they may include persistent changes in bowel habits (e.g., diarrhea, constipation, or narrowing of stool), rectal bleeding or blood in stool, unexplained abdominal discomfort or cramping, iron-deficiency anemia, unintentional weight loss, or fatigue. Diagnosis relies on endoscopic visualization with biopsy confirmation, supplemented by cross-sectional imaging (CT/MRI) and molecular profiling (e.g., MSI/MMR status, RAS/BRAF mutations) to guide prognosis and therapy. Treatment is multidisciplinary: localized disease is primarily managed with surgical resection (laparoscopic or robotic-assisted colectomy/low anterior resection); locally advanced or node-positive cases often require adjuvant chemotherapy (e.g., FOLFOX or CAPEOX); and metastatic disease may involve systemic therapy (chemotherapy, targeted biologics like anti-EGFR or anti-VEGF agents), immunotherapy (for MSI-H/dMMR tumors), and metastasectomy when feasible. Beyond survival, CRC profoundly impacts quality of life—physically (bowel dysfunction, stoma-related challenges, neuropathy), psychologically (anxiety, depression, body image concerns), socially (work disruption, caregiving burden), and economically (out-of-pocket costs, lost productivity). Survivorship care emphasizes surveillance colonoscopy, nutritional support, physical rehabilitation, and psychosocial counseling to mitigate long-term sequelae and optimize functional recovery.

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. In the Department of Gastroenterology, management emphasizes early detection, risk stratification, and multimodal therapeutic integration. Treatment selection depends on tumor stage (per TNM classification), molecular profile (e.g., microsatellite instability [MSI], RAS/BRAF mutation status), patient performance status, comorbidities, and treatment goals—curative versus palliative.

Conservative (non-surgical) management is primarily indicated for select early-stage lesions and unresectable or metastatic disease. For localized T1 adenocarcinomas confined to the submucosa without high-risk features (lymphovascular invasion, poor differentiation, positive margins), endoscopic resection—including endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)—is considered definitive conservative therapy. These minimally invasive techniques preserve colonic anatomy and function, with 5-year recurrence rates <5% in appropriately selected cases. In locally advanced rectal cancer (cT3–4 or N+), neoadjuvant chemoradiotherapy (nCRT) remains standard: typically 50.4 Gy radiation delivered over 5–6 weeks combined with concurrent 5-fluorouracil (5-FU) or capecitabine. This approach achieves pathologic complete response (pCR) in ~15–25% of patients, enabling organ-preserving 'watch-and-wait' strategies under rigorous endoscopic and MRI surveillance—avoiding radical surgery in carefully monitored responders.

Pharmacotherapy is central across all stages. Adjuvant chemotherapy (e.g., FOLFOX [5-FU, leucovorin, oxaliplatin] or CAPEOX [capecitabine + oxaliplatin]) is recommended for stage III and high-risk stage II CRC following curative resection, reducing recurrence risk by 30–40%. For metastatic CRC (mCRC), systemic therapy is the cornerstone. First-line regimens include doublets (FOLFOX or FOLFIRI [5-FU, leucovorin, irinotecan]) or triplets (FOLFOXIRI) ± biologic agents. Anti-EGFR monoclonal antibodies (cetuximab, panitumumab) are reserved for RAS/BRAF wild-type left-sided tumors; anti-VEGF agents (bevacizumab, aflibercept, ramucirumab) are agnostic to sidedness or mutational status. Immunotherapy has revolutionized care for MSI-H/dMMR mCRC: pembrolizumab or nivolumab ± ipilimumab yields durable responses in >40% of patients, with median progression-free survival exceeding 16 months. Targeted therapies such as encorafenib + cetuximab are approved for BRAF V600E-mutant CRC. Maintenance therapy (e.g., 5-FU/capecitabine ± bevacizumab) after induction improves tolerability without compromising efficacy.

Surgical resection remains the only potentially curative modality for non-metastatic CRC. Laparoscopic colectomy is now standard-of-care for colon cancer, offering equivalent oncologic outcomes to open surgery with reduced postoperative pain, shorter hospital stays (median 4–5 days), and faster return to baseline function. For rectal cancer, total mesorectal excision (TME) is mandatory to achieve negative circumferential resection margins (CRM). Low anterior resection (LAR) preserves the anal sphincter in mid- to upper-rectal tumors, while abdominoperineal resection (APR) is reserved for low-lying tumors involving the distal rectum or anal canal. Transanal total mesorectal excision (TaTME) and robotic-assisted platforms enhance precision in narrow pelvic anatomy, particularly for male or obese patients. In select cases of synchronous liver-limited metastases, simultaneous or staged resection (with or without perioperative chemotherapy) may achieve long-term survival in 30–50% of patients.

China offers distinct advantages in CRC management. First, nationwide endoscopic screening programs—especially in urban centers like Shanghai, Beijing, and Guangzhou—leverage high-volume, standardized colonoscopy with AI-assisted real-time polyp detection (e.g., EndoAngel), improving adenoma detection rates by up to 25%. Second, China’s robust generic drug ecosystem ensures rapid, affordable access to biosimilars (e.g., cetuximab and bevacizumab biosimilars approved since 2020) and oral fluoropyrimidines, reducing out-of-pocket costs by >60% compared with Western markets. Third, integrated multidisciplinary tumor boards (MDTs) are mandated in Grade III hospitals, ensuring coordinated input from gastroenterologists, surgical oncologists, medical oncologists, radiologists, and pathologists within 72 hours of diagnosis. Fourth, China leads globally in clinical trial enrollment for novel CRC therapeutics—accounting for ~35% of Asia-Pacific phase III trials—and offers early-access programs for breakthrough agents like KRAS G12C inhibitors (adagrasib) and dual checkpoint inhibitors. Finally, standardized national guidelines (CSCO and CSOG) harmonize evidence-based practice across tiers of care, minimizing regional disparities.

Post-treatment recovery requires structured, multidisciplinary support. Patients undergoing resection should initiate early mobilization (ambulation within 6–12 hours post-op) to reduce ileus and thromboembolic risk. Dietary advancement begins with clear liquids on postoperative day one, progressing to low-residue then regular diet by day five—fiber reintroduction is gradual to prevent bloating. For those with stoma, certified enterostomal therapists provide pre- and postoperative counseling, appliance fitting, and skin integrity management. Chemotherapy recipients require proactive symptom control: cryotherapy for oxaliplatin-induced neuropathy, dose-modified schedules for hematologic toxicity, and nutritional supplementation (vitamin B12, iron, folate) for anemia or malabsorption. Surveillance follows CSCO protocols: colonoscopy at 1 year post-resection (or 6 months if incomplete initial exam), then every 3 years if normal; CEA monitoring every 3 months for 2 years, then every 6 months through year 5; CT chest/abdomen/pelvis every 6–12 months for stage II–III disease. Psychosocial support—including oncology-certified counseling and peer-led survivorship groups—is integral, given the high prevalence of anxiety (32%) and depression (24%) in CRC survivors. Long-term lifestyle modification is strongly encouraged: ≥150 minutes/week moderate exercise, Mediterranean-style diet rich in whole grains and cruciferous vegetables, smoking cessation, and alcohol moderation (<1 drink/day)—each independently associated with 20–30% reduction in recurrence risk. With comprehensive, stage-adapted care, 5-year overall survival exceeds 90% for stage I, 75–85% for stage II, 60–70% for stage III, and 15–25% for stage IV disease—underscoring the critical importance of timely diagnosis and personalized intervention.